Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Bepotastine besilate
Drug ID BADD_D00253
Description Bepotastine is a non-sedating, selective antagonist of the histamine 1 (H1) receptor. Bepotastine was approved in Japan for use in the treatment of allergic rhinitis and uriticaria/puritus in July 2000 and January 2002, respectively, and is marketed by Tanabe Seiyaku Co., Ltd. under the brand name Talion. It is available in oral and opthalmic dosage forms in Japan. The opthalmic solution is FDA approved since Sept 8, 2009 and is under the brand name Bepreve.
Indications and Usage For the symptomatic treatment of itchy eyes (caused by IgE-induced mast cell degranulation) due to allergic conjunctivitis.
Marketing Status Prescription
ATC Code Not Available
DrugBank ID DB04890
KEGG ID D01654
MeSH ID C511534
PubChem ID 164521
TTD Drug ID Not Available
NDC Product Code 40700-0040; 14501-0088; 24208-629; 0378-7055; 60505-6111; 16436-0106; 24208-630
Synonyms bepotastine besilate
Chemical Information
Molecular Formula C27H31ClN2O6S
CAS Registry Number 190786-44-8
SMILES C1CN(CCC1OC(C2=CC=C(C=C2)Cl)C3=CC=CC=N3)CCCC(=O)O.C1=CC=C(C=C1)S(=O)(=O)O
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Dysgeusia07.14.03.001; 17.02.07.003--
Eye irritation06.04.05.003--Not Available
Headache17.14.01.001--
Lip swelling23.04.01.007; 10.01.05.005; 07.05.04.005--Not Available
Nasopharyngitis22.07.03.002; 11.01.13.002--Not Available
Pharyngeal oedema23.04.01.016; 22.04.05.003; 10.01.05.016--Not Available
Pruritus23.03.12.001--
Rash23.03.13.001--Not Available
Swollen tongue23.04.01.014; 10.01.05.015; 07.14.02.003--Not Available
The 1th Page    1    Total 1 Pages